The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients

Diabetes Res Clin Pract. 2008 Jul;81(1):56-60. doi: 10.1016/j.diabres.2008.02.006. Epub 2008 Mar 21.


The aim of the study was to evaluate the effect of metformin on markers of endothelial function, vascular inflammation and factors of thrombosis in obese type 2 diabetic patients. Twenty-four type 2 diabetic patients (15 female, 9 male) previously under medical nutrition treatment (MNT)+regular exercise programme (REP) without chronic micro or macrovascular complications with the mean age of 50.5+/-1.5 years, diabetes duration of 17.9+/-6.3 months and body mass index (BMI) of 31.7+/-0.8 kg/m(2) were enrolled in the study. In the first 4 weeks, all the patients continued MNT+REP. In the following 12 weeks, metformin (mean daily dosage of 1381+/-85 mg) was added. After the first period with MNT+REP, BMI, waist circumference, fat percentage, blood pressure and HDL cholesterol decreased significantly. After metformin addition, there was a significant decrement in BMI, waist circumference, fat percentage, fasting and postprandial plasma glucose, hemoglobin A1C, plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor (VEGF) and increment in beta cell reserve values of the patients. Our results indicated that, metformin addition had beneficial effect on VEGF and PAI-1 levels in obese type 2 diabetic patients under MNT+REP, independent from its' favourable effects on BMI and glycemic control.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Aged
  • Blood Glucose / metabolism
  • Body Mass Index
  • Diabetes Mellitus, Type 2 / blood*
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Exercise
  • Female
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Lipids / blood
  • Male
  • Matrix Metalloproteinase 9 / blood
  • Metformin / therapeutic use*
  • Middle Aged
  • Obesity / blood*
  • Obesity / complications
  • Obesity / physiopathology
  • Plasminogen Activator Inhibitor 1 / blood*
  • Prospective Studies
  • Vascular Endothelial Growth Factor A / blood*
  • Waist-Hip Ratio


  • Blood Glucose
  • Hypoglycemic Agents
  • Lipids
  • Plasminogen Activator Inhibitor 1
  • Vascular Endothelial Growth Factor A
  • Metformin
  • Matrix Metalloproteinase 9